Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allogeneic Mesenchymal Bone Marrow Cells Clear all
Completed Phase 2 Interventional Results available

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

NCT03818854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Human Mesenchymal Stromal Cells, Cell Reconstitution Media
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 28, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Results available

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

NCT01775774
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 28, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

Allogeneic BM-MSCs in Patients With Painful Lumbar Facet Arthropathy

NCT06001853
View directory record Official record
Conditions
Facet-Mediated Low Back Pain, Lumbar Facet Joint Osteoarthritis
Interventions
BM-MSC injection, DSMO Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

NCT06918808
View directory record Official record
Conditions
Perianal Fistula Due to Crohn's Disease
Interventions
DB-3Q, Placebo
Biological
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

NCT04543994
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

NCT02408432
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 28, 2026, 4:56 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Using Allogeneic Bone-marrow Derived Human Mesenchymal Stem Cells (Allo-hMSC) for a Individual Parkinson's Disease Subject

NCT06798064
View directory record Official record
Conditions
Parkinson Disease
Interventions
Allogeneic bone marrow-derived mesenchymal stem cells
Biological
Lead sponsor
Mya Schiess
Other
Eligibility
50 Years to 80 Years
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 28, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

NCT04548583
View directory record Official record
Conditions
Crohn Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells

NCT05925608
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs), Diagnostic Catheterization
Combination Product · Diagnostic Test
Lead sponsor
BioCardia, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 28, 2026, 4:56 PM EDT
Suspended Phase 1 Interventional

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

NCT02962661
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

NCT02611167
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 28, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure

NCT02467387
View directory record Official record
Conditions
Non-Ischemic Heart Failure
Interventions
Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer's Solution
Drug
Lead sponsor
CardioCell LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 28, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

NCT05176366
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
ExoFlo
Biological
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 28, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer

NCT01983709
View directory record Official record
Conditions
Prostate Cancer
Interventions
Allogeneic Human Mesenchymal Stem Cells
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 28, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

NCT05130983
View directory record Official record
Conditions
Crohn Disease, Inflammatory Bowel Diseases
Interventions
ExoFlo
Biological
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 28, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease

NCT04519684
View directory record Official record
Conditions
Ileal Pouch, Crohn Disease
Interventions
Mesenchymal stem cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

NCT00136903
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone, Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 28, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ExoFlo for the Treatment of Perianal Fistulas

NCT05836883
View directory record Official record
Conditions
Perianal Fistula, Crohn's Disease
Interventions
ExoFlo, Local injection of normal saline
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

NCT03929120
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Diseases
Interventions
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 28, 2026, 4:56 PM EDT
Recruiting Phase 1 Interventional

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

NCT03896568
View directory record Official record
Conditions
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
Interventions
Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging

NCT01771679
View directory record Official record
Conditions
Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Interventions
Allogeneic Mesenchymal Bone Marrow Cells
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 28, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

NCT02097641
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 28, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

NCT04519671
View directory record Official record
Conditions
Perianal Crohn Disease, Perianal Fistula, Crohn Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 28, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

NCT00705120
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan
Other · Radiation · Drug + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2008 · Synced Sep 28, 2026, 4:56 PM EDT